Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2876513 | 0.94 | KDM4E (0.50) | KDM4EMTNR1AMTNR1BFBP1PPARD | |
| SCHEMBL4607275 | 0.90 | CYP3A4 (0.51) | CHRNB2CHRNA4CYP3A4HIF1AFBP1 | |
| SCHEMBL5892268 | 0.87 | PPARA (0.47) | KDM4EMTNR1AMTNR1BFBP1PPARD | |
| SCHEMBL5892294 | 0.86 | PPARA (0.46) | KDM4EMTNR1AMTNR1BFBP1PPARD | |
| SCHEMBL5737876 | 0.83 | CYP3A4 (0.45) | CYP3A4PPARA | |
| SCHEMBL13069642 | 0.81 | CES2 (0.49) | MTNR1AMTNR1B | |
| SCHEMBL197882 | 0.77 | PPARA (0.64) | CNR1CYP3A4FBP1PPARA | |
| SCHEMBL6310133 | 0.76 | MRGPRX4 (0.54) | PPARDPPARA | |
| SCHEMBL1470185 | 0.76 | CHRNB2 (0.69) | CHRNB2CHRNA4CNR1CNR2DRD2 | |
| SCHEMBL29510932 | 0.76 | CHRNB2 (0.69) | CHRNB2CHRNA4CNR1CNR2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027098-A1 | Derivatives of alpha-phenylthiocarboxylic and alpha-phenyloxy-carboxylic acids useful for the treatment of diseases responding to PPARalpha activation | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-01-31 | — | — | US | claimed |
| WO-2004113266-A1 | DERIVATIVES OF PHENYLALKYL AND PHENOXYALKYL ACIDS FOR THE TREATMENT OF THE HYPERGLYCAEMIA AND HYPERTRIGLYCERIDAEMIA AND TYPE 2 DIABETES AND PROCESS FOR PREPARING THEM | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-12-29 | — | — | WO | claimed |
| EP-1474387-B1 | DERIVATIVES OF ALPHA-PHENYLTHIOCARBOXYLIC AND ALPHA-PHENYLOXY-CARBOXYLIC ACIDS USEFUL FOR THE TREATMENT OF DISEASES RESPONDING TO PPAR ALPHA ACTIVATION | SIGMA TAU IND FARMACEUTI (IT) | 2010-11-24 | — | — | EP | disclosed |
| US-20080027098-A1 | Derivatives of alpha-phenylthiocarboxylic and alpha-phenyloxy-carboxylic acids useful for the treatment of diseases responding to PPARalpha activation | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-01-31 | — | — | US | disclosed |
| US-20050054671-A1 | Derivatives of alpha-phenylthiocarboxylic and $g(a)-phenyloxy-carboxylic acids useful for the treatment of diseases responding to pparalpha activation | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P. A | 2005-03-10 | — | — | US | disclosed |
| WO-2004113266-A1 | DERIVATIVES OF PHENYLALKYL AND PHENOXYALKYL ACIDS FOR THE TREATMENT OF THE HYPERGLYCAEMIA AND HYPERTRIGLYCERIDAEMIA AND TYPE 2 DIABETES AND PROCESS FOR PREPARING THEM | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027098-A1 | Derivatives of alpha-phenylthiocarboxylic and alpha-phenyloxy-carboxylic acids useful for the treatment of diseases responding to PPARalpha activation | PPARA, PPARD, PPARG | CHRNB2 4168/4885CHRNA4 4196/4885KDM4E 3576/4885 |
| US-20050054671-A1 | Derivatives of alpha-phenylthiocarboxylic and $g(a)-phenyloxy-carboxylic acids useful for the treatment of diseases responding to pparalpha activation | PPARG, PPARA, PPARD | CHRNB2 4249/4885CHRNA4 4007/4885KDM4E 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.